BioCryst Pharmaceuticals reported a remarkable turnaround in fiscal year 2025, posting $341 million in operating income after years of substantial losses. This shift was driven primarily by a 37% year-over-year surge in revenues from its oral hereditary angioedema (HAE) treatment, ORLADEYO, alongside strategic expansion via the merger with Astria Therapeutics. The merger, financed through a $400 million term loan, supports pipeline diversification but introduces leverage considerations. Strong liquidity metrics and substantial operating cash flow underpin BioCryst's improved financial footing, although risks remain tied to ORLADEYO’s market performance and regulatory environment.